We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A combination of daratumumab (Janssen’s Darzalex) and atezolizumab (Roche’s Tecentriq) has failed to show any benefit over the latter alone in a mid-stage trial involving patients with pre-treated metastatic non-small cell lung cancer.